Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on Taro Pharmaceutical Indus, Lowers Price Target to $35

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Taro Pharmaceutical Indus (NYSE:TARO) with a Buy and lowers the price target from $54 to $35.
byBenzinga Newsdesk
January 25, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Taro Pharmaceutical Indus (NYSE:TARO) with a Buy and lowers the price target from $54 to $35.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts